News Daiichi Sankyo Company, Limited

Equities

4568

JP3475350009

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 06:30:00 10/02/2026 GMT			5-day change	1st Jan Change
2,983.50 ^JPY	+1.07%		+1.65%	-10.89%

02-04	Daiichi Sankyo Announces First Patient Has Been Dosed in A First-In-Human Phase 1/2 Trial	CI
02-03	AstraZeneca says FDA backs Datroway, seeks more assurance on Saphnelo	AN

02-09	Daiichi Sankyo : Support for Victims of Floods in Southeast and South Asia	PU
02-04	Daiichi Sankyo Announces First Patient Has Been Dosed in A First-In-Human Phase 1/2 Trial	CI
02-04	DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo	BU
02-03	AstraZeneca says FDA backs Datroway, seeks more assurance on Saphnelo	AN
02-03	AstraZeneca Says Breast Cancer Treatment Granted US FDA Priority Review	MT
02-03	Daiichi Sankyo And AstraZeneca Receive Priority Review For DATROWAY For Treatment Of Unresectable Or Metastatic Triple Negative Breast Cancer In The U.S	CI
02-03	AG Barr adds drink brands; Filtronic profit falls	AN
02-03	AstraZeneca, Daiichi Sankyo's Breast Cancer Treatment Wins US Priority Review Status	MT
02-03	DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy	BU
02-02	Nikkei slides on tech, resources sell-off despite weaker yen	RE
01-30	Daiichi Sankyo Company, Limited, Q3 2026 Earnings Call, Jan 30, 2026
01-30	Daiichi Sankyo : Notice on the Determined Basic Policy for Absorption-type Merger of Daiichi Sankyo with Its Wholly Owned Subsidiary, Daiichi Sankyo Business Associe (Simplified Merger/Short Form Merger)	PU
01-30	Daiichi Sankyo's Nine-Month Profit Rises 4%	MT
01-30	Daiichi Sankyo : FY2025 Q3 Financial ResultsPDF	PU
01-30	Daiichi Sankyo : FY2025 Q3 Reference DataPDF	PU
01-30	Daiichi Sankyo : FY2025 Q3 Presentation MaterialPDF	PU
01-30	Daiichi Sankyo Company, Limited Reports Earnings Results for the Nine Months Ended December 31, 2025	CI
01-28	Berenberg Ups AstraZeneca Price Target on Datroway's Sales Potential in Lung Cancer	MT
01-22	Daiichi and AstraZeneca's Enhertu wins sixth approval in China	AN
01-22	Daiichi Sankyo : ENHERTU® Approved in China as the First and Only HER2 Directed ADC for the Second-Line Treatment of Patients with HER2 Positive Metastatic Gastric Cancer	PU
01-22	Daiichi Sankyo Appoints Veronika Rozehnal, Ph.D., as Head of Translational Research Center Europe	CI
01-22	Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe	BU
01-21	National Medical Products Administration Approves Enhertu in China as the First and Only Her2 Directed Dc for the Second-Line Treatment of Patients with Her2 Positive Metastatic Gastric Cancer	CI
01-21	Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology	AQ
01-20	European Stocks Close Lower in Tuesday Trading; UK Unemployment Rises to 5.1%	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Daiichi Sankyo: Voluntary withdrawal of MAA in the EU for Dato-DXd

December 31, 2024 at 12:23 pm

Daiichi Sankyo: Will Boost ADC Cancer Drug Production

October 11, 2024 at 09:08 am